Nicotinamides as JAK kinase modulators
US9102625B2 · kind B2 · utility
4Cited by
32References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 1, 2011 |
| Grant date | Aug 11, 2015 |
| Priority date | — |
| Expiry date | May 2, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.